11 Result(s)

Article

Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer – a multi-centre randomised phase II study

No standard treatment for locally advanced pancreatic cancer (LAPC) is defined.

R Wilkowski, S Boeck, S Ostermaier, R Sauer, M Herbst… in British Journal of Cancer (2009)

Article

Reply to: The definition of locally advanced pancreatic cancer

S Boeck, V Heinemann in British Journal of Cancer (2010)

Article

Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer

New therapeutic options for metastatic pancreatic cancer are urgently needed. In pancreatic cancer, overexpression of the epidermal growth factor receptor 2 (HER2) has been reported in up to 45%. This multicen...

J Harder, G Ihorst, V Heinemann, R Hofheinz, M Moehler… in British Journal of Cancer (2012)

Article

EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104

We aimed to identify molecular epidermal growth factor receptor (EGFR) tissue biomarkers in pancreatic cancer (PC) patients treated with the anti-EGFR agent erlotinib within the phase 3 randomised AIO-PK0104 s...

S Boeck, A Jung, R P Laubender, J Neumann, R Egg, C Goritschan… in British Journal of Cancer (2013)

Article

Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer

To evaluate the efficacy and tolerability of the urokinase plasminogen activator (uPA) inhibitor upamostat in combination with gemcitabine in locally advanced pancreatic adenocarcinoma (LAPC).

V Heinemann, M P Ebert, R P Laubender, P Bevan, C Mala… in British Journal of Cancer (2013)

Article

Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer

CYFRA 21-1 serves as biomarker in several epithelial malignancies. However, its role in pancreatic cancer (PC) has not yet been investigated.

S Boeck, C Wittwer, V Heinemann, M Haas, C Kern, P Stieber… in British Journal of Cancer (2013)

Article

Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial

AIO KRK-0104 investigated first-line therapy of metastatic colorectal cancer (mCRC) with cetuximab, capecitabine and irinotecan versus cetuximab, capecitabine and oxaliplatin. This analysis investigated the im...

J. C. von Einem, V. Heinemann… in Journal of Cancer Research and Clinical On… (2014)

Article

Neoadjuvant chemotherapy in pancreatic cancer: innovative, but still difficult

S Boeck, M Haas, S Ormanns, S Kruger, J T Siveke, V Heinemann in British Journal of Cancer (2014)

Article

R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007± trial

Chemotherapy with or without radiotherapy is the standard in patients with initially nonmetastatic unresectable pancreatic cancer. Additional surgery is in discussion. The CONKO-007 multicenter randomized tria...

Prof. Dr. R. Fietkau, R. Grützmann, U. A. Wittel… in Strahlentherapie und Onkologie (2021)

Article

Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel

This pilot study aimed on generating insight on alterations in circulating immune cells during the use of FOLFIRINOX and gemcitabine/nab-paclitaxel in pancreatic ductal adenocarcinoma (PDAC).

L. Sams, S. Kruger, V. Heinemann, D. Bararia… in Clinical and Translational Oncology (2021)

Article

Cancer of unknown primary (CUP) through the lens of precision oncology: a single institution perspective

For patients with cancer of unknown primary (CUP), treatment options are limited. Precision oncology, the interplay of comprehensive genomic profiling (CGP) and targeted therapies, aims to offer additional tre...

L. Weiss, K. Heinrich, D. Zhang, K. Dorman… in Journal of Cancer Research and Clinical On… (2023)